These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures. Pae CU; Bodkin JA; Portland KB; Thase ME; Patkar AA J Clin Psychiatry; 2012 May; 73(5):661-8. PubMed ID: 22697192 [TBL] [Abstract][Full Text] [Related]
25. Comparative fasting bioavailability of dispersible and conventional tablets of risperidone: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy male Chinese volunteers. Huang M; Shen-Tu J; Hu X; Chen J; Liu J; Wu L Clin Ther; 2012 Jun; 34(6):1432-9. PubMed ID: 22595151 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. Mascher HJ; Kikuta C; Millendorfer A; Schiel H; Ludwig G Int J Clin Pharmacol Ther; 1997 Jan; 35(1):9-13. PubMed ID: 9021435 [TBL] [Abstract][Full Text] [Related]
27. A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion. Harris DS; Everhart T; Jacob P; Lin E; Mendelson JE; Jones RT BMC Clin Pharmacol; 2009 Aug; 9():13. PubMed ID: 19646280 [TBL] [Abstract][Full Text] [Related]
28. Why the transdermal delivery of selegiline (6 mg/24 hr) obviates the need for a dietary restriction on tyramine. Preskorn SH J Psychiatr Pract; 2006 May; 12(3):168-72. PubMed ID: 16732136 [No Abstract] [Full Text] [Related]
29. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189 [TBL] [Abstract][Full Text] [Related]
30. Selegiline transdermal system: in the treatment of major depressive disorder. Frampton JE; Plosker GL Drugs; 2007; 67(2):257-65; discussion 266-7. PubMed ID: 17284087 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine. Hall J; Naranjo CA; Sproule BA; Herrmann N J Clin Psychopharmacol; 2003 Aug; 23(4):349-57. PubMed ID: 12920410 [TBL] [Abstract][Full Text] [Related]
32. Selegiline transdermal system in major depressive disorder: profile report. Frampton JE; Plosker GL CNS Drugs; 2007; 21(6):521-4. PubMed ID: 17521230 [No Abstract] [Full Text] [Related]
33. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability. Robinson DS; Amsterdam JD J Affect Disord; 2008 Jan; 105(1-3):15-23. PubMed ID: 17568687 [TBL] [Abstract][Full Text] [Related]
34. Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale. Clayton AH; Campbell BJ; Favit A; Yang Y; Moonsammy G; Piontek CM; Amsterdam JD J Clin Psychiatry; 2007 Dec; 68(12):1860-6. PubMed ID: 18162016 [TBL] [Abstract][Full Text] [Related]
35. Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline. Palovaara S; Anttila M; Nyman L; Laine K Eur J Clin Pharmacol; 2002 Jul; 58(4):259-63. PubMed ID: 12136372 [TBL] [Abstract][Full Text] [Related]
36. Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males. Barrett JS; Szego P; Rohatagi S; Morales RJ; De Witt KE; Rajewski G; Ireland J Pharm Res; 1996 Oct; 13(10):1535-40. PubMed ID: 8899847 [TBL] [Abstract][Full Text] [Related]
37. An evaluation of risperidone drug interactions. DeVane CL; Nemeroff CB J Clin Psychopharmacol; 2001 Aug; 21(4):408-16. PubMed ID: 11476125 [TBL] [Abstract][Full Text] [Related]
38. Transdermal selegiline and intravenous cocaine: safety and interactions. Houtsmuller EJ; Notes LD; Newton T; van Sluis N; Chiang N; Elkashef A; Bigelow GE Psychopharmacology (Berl); 2004 Feb; 172(1):31-40. PubMed ID: 14605792 [TBL] [Abstract][Full Text] [Related]
39. Absence of acute cocaine interactions with the MAO-B inhibitor selegiline. Haberny KA; Walsh SL; Ginn DH; Wilkins JN; Garner JE; Setoda D; Bigelow GE Drug Alcohol Depend; 1995 Jul; 39(1):55-62. PubMed ID: 7587975 [TBL] [Abstract][Full Text] [Related]
40. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Elkashef A; Fudala PJ; Gorgon L; Li SH; Kahn R; Chiang N; Vocci F; Collins J; Jones K; Boardman K; Sather M Drug Alcohol Depend; 2006 Dec; 85(3):191-7. PubMed ID: 16730924 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]